UY34504A - Prevención de los efectos adversos causados por los anticuerpos biespecíficos EpCAMxCD3 - Google Patents

Prevención de los efectos adversos causados por los anticuerpos biespecíficos EpCAMxCD3

Info

Publication number
UY34504A
UY34504A UY0001034504A UY34504A UY34504A UY 34504 A UY34504 A UY 34504A UY 0001034504 A UY0001034504 A UY 0001034504A UY 34504 A UY34504 A UY 34504A UY 34504 A UY34504 A UY 34504A
Authority
UY
Uruguay
Prior art keywords
epcamxcd3
prevention
adverse effects
bispecific antibodies
effects caused
Prior art date
Application number
UY0001034504A
Other languages
English (en)
Inventor
Sabine Kaubitzsch Stienen
Original Assignee
Amgen Res Munich Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Res Munich Gmbh filed Critical Amgen Res Munich Gmbh
Publication of UY34504A publication Critical patent/UY34504A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Un glucocorticoide (GC) que puede usarse en la mejora, el tratamiento y/o la profilaxis de los efectos adversos hepáticos y/o gastroenterológicos que son causados por el anticuerpo biespecífico EpCAMxCD3, donde la administración del GC se inicia antes de la administración del anticuerpo biespecífico EpCAMxCD3. Conjuntos de elementos que comprenden un GC, un anticuerpo biespecífico EpCAMxCD3 e instrucciones de uso donde se indica que el GC ha de emplearse en el tratamiento, la mejora y/o la profilaxis de los efectos adversos hepáticos y/o gastroenterológicos que son causados por el anticuerpo biespecífico EpCAMxCD3 en un paciente.
UY0001034504A 2011-12-09 2012-12-07 Prevención de los efectos adversos causados por los anticuerpos biespecíficos EpCAMxCD3 UY34504A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161569180P 2011-12-09 2011-12-09

Publications (1)

Publication Number Publication Date
UY34504A true UY34504A (es) 2013-06-28

Family

ID=47520027

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001034504A UY34504A (es) 2011-12-09 2012-12-07 Prevención de los efectos adversos causados por los anticuerpos biespecíficos EpCAMxCD3

Country Status (5)

Country Link
AR (1) AR089114A1 (es)
AU (1) AU2012350429A1 (es)
TW (1) TW201322985A (es)
UY (1) UY34504A (es)
WO (1) WO2013083809A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006114115A1 (de) 2005-04-26 2006-11-02 Trion Pharma Gmbh Kombination von antikörpern mit glukokortikoiden zur behandlung von krebs
CA2986254A1 (en) 2015-05-18 2016-11-24 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
IL302614A (en) 2017-09-08 2023-07-01 Maverick Therapeutics Inc Binding proteins are activated under limited conditions
CN114390938A (zh) 2019-03-05 2022-04-22 武田药品工业有限公司 受约束的条件性活化的结合蛋白
WO2023044039A1 (en) * 2021-09-16 2023-03-23 TCR2 Therapeutics Inc. Compositions and methods for treating cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
EP0623679B1 (en) 1987-05-21 2003-06-25 Micromet AG Targeted multifunctional proteins
RU2005137325A (ru) 2003-05-31 2006-09-10 Микромет Аг (De) Фармацевтическая композиция, содержащая конструкт, специфичный к ерсам
NZ546173A (en) 2003-10-16 2009-04-30 Micromet Ag Multispecific deimmunized CD3-binders
WO2006114115A1 (de) * 2005-04-26 2006-11-02 Trion Pharma Gmbh Kombination von antikörpern mit glukokortikoiden zur behandlung von krebs
MX2009010611A (es) 2007-04-03 2010-03-26 Micromet Ag Enlazadores biespecificos, especificos para especies.
RS53008B2 (sr) 2007-04-03 2022-12-30 Amgen Res Munich Gmbh Interspecijski specifičan cd3-epsilon vezujući domen
EP2370467B1 (en) 2008-10-01 2016-09-07 Amgen Research (Munich) GmbH Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxc d3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody
CN102711825A (zh) 2009-09-18 2012-10-03 米克罗麦特股份公司 用于施用EpCAMxCD3双特异性抗体的给药方案

Also Published As

Publication number Publication date
WO2013083809A1 (en) 2013-06-13
AR089114A1 (es) 2014-07-30
AU2012350429A1 (en) 2013-07-11
TW201322985A (zh) 2013-06-16

Similar Documents

Publication Publication Date Title
UY34206A (es) Anticuerpo monoclonal de interleucina-31
UY33925A (es) Inhibidores tricíclicos de quinasas
CR20130278A (es) Prevención de los efectos adversos causados por dominio de unión específicos cd3
UY34156A (es) Compuestos inhibidores de metaloenzimas
CR20140024A (es) Compuestos inhibidores de metaloenzimas
EA201692412A1 (ru) Синтез полициклических карбамоилпиридоновых соединений
UY34410A (es) Inmunoligantes biespecificos dirigidos contra tnf
UY34456A (es) Anticuerpos anti-il-36r
UY34145A (es) Compuestos inhibidores de metaloenzimas
UA109931C2 (xx) Піримідинциклогексильні модулятори глюкокортикоїдних рецепторів
UY34472A (es) Derivados modificados de 4-fenil-piridina
UY33958A (es) Inhibidores de la glucosilceramida sintasa
UY33977A (es) Híbrido de pigmento autoaglutinante.
CR20130539A (es) Triazolopiridinas
UY33931A (es) Agentes de union biespecificos
UY34654A (es) Inhibidores de la beta-secretasa
EA201391389A1 (ru) Кристаллы антител против склеростина и составы на их основе
UY33930A (es) Inhibidores novedosos de quinasas
UY34074A (es) Composición oftálmica de olopatadina altamente concentrada
UY33957A (es) Moduladores de los receptores de hormonas nucleares
UY34006A (es) Imidazopiridazinas
UY34158A (es) Composicion herbicida
UY34141A (es) Composiciones de limpieza de sal líquida
UY34329A (es) Compuestos de triazolopiridina
UY4153Q (es) Batería

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20201020